Most Targeted Cancer Drugs Lack Substantial Clinical Benefit

Source link :

TOPLINE: An analysis of molecular-targeted cancer drug therapies recently approved in the United States found that fewer than one third demonstrated substantial clinical benefits at the time of approval. METHODOLOGY: The strength and quality of evidence supporting genome-targeted cancer drug approvals vary. A big reason is the growing number of cancer drug approvals based on […]

Author : News Health

Publish date : 2024-04-16 13:14:43

Copyright for syndicated content belongs to the linked Source.